Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.51 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1788806 | 0.92 | HRH3 (0.54) | HRH3KDM2BMAPK14CYP2D6 | |
| SCHEMBL1787758 | 0.90 | HRH3 (0.53) | HRH3KDM2B | |
| SCHEMBL12608452 | 0.90 | MAPT (0.53) | HRH3KDM2B | |
| SCHEMBL1789634 | 0.90 | HRH3 (0.57) | HRH3MAPK14CYP2D6 | |
| SCHEMBL1789723 | 0.89 | HRH3 (0.66) | HRH3KDM2BNR1H4EPHX2MAPK14 | |
| SCHEMBL1786902 | 0.88 | HRH3 (0.53) | HRH3KDM2BMAPK14 | |
| SCHEMBL1791891 | 0.88 | HRH3 (0.50) | HRH3KDM2B | |
| SCHEMBL1787454 | 0.87 | HRH3 (0.58) | HRH3 | |
| SCHEMBL1790574 | 0.87 | HRH3 (0.50) | HRH3KDM2BMAPK14 | |
| SCHEMBL1789917 | 0.86 | ALDH1A1 (0.48) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | HRH3 2/4885KDM2B 1549/4885NR1H4 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.